We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
The Tycoon Herald
  • Trending
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Money
    • Crypto / NFT
  • Innovation
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Leadership
  • Health
  • Sports
  • Entertainment
Reading: Medicare Won’t Pay For Controversial Alzheimer’s Drug Aduhelm Without A New Trial
Sign In
The Tycoon HeraldThe Tycoon Herald
Font ResizerAa
Search
  • Trending
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Money
    • Crypto / NFT
  • Innovation
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Leadership
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© Tycoon Herald. All Rights Reserved.
Medicare Won’t Pay For Controversial Alzheimer’s Drug Aduhelm Without A New Trial
The Tycoon Herald > Money > Medicare Won’t Pay For Controversial Alzheimer’s Drug Aduhelm Without A New Trial
Money

Medicare Won’t Pay For Controversial Alzheimer’s Drug Aduhelm Without A New Trial

Tycoon Herald
By Tycoon Herald 3 Min Read Published January 11, 2022
Share
SHARE

FILE – The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. (AP Photo/Steven … [+] Senne, File)

ASSOCIATED PRESS

In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial.  

In bureaucratic language: “Monoclonal antibodies directed against amyloid for the treatment of [Alzheimer’s Disease] provided outside of the CMS approved randomized controlled trials and trials supported by the NIH are nationally non-covered.” The determination is a draft, which is now subject to 30 days of public comment. CMS will issue its final coverage decision in April.

It is likely that private insurers will follow Medicare lead and refuse to pay for the drug. Manufacturer Biogen’s initial price for Aduhelm was $56,000-a-year for a typical patient. Faced with resistance from most physicians and little demand, Biogen cut the price in half to $28,000 in December. But even that price is far too steep for consumers to pay out-of-pocket.

Not commercially viable

Without Medicare or private insurance coverage, or absent a further steep price cut, the drug does not appear to be commercially viable. Several other drug makers are working on similar monoclonal antibody treatments for Alzheimer’s Disease.     

CMS said that it wants the trial to study two issues: Do Aduhelm and similar drugs result in “statistically significant and clinically meaningful difference in decline in cognition and function” and what adverse events does they cause?

MORE FOR YOU

The agency said it would pay for the drug as well as a necessary positron emission tomography (PET) scan only for subjects in the approved trial.

Controversial FDA approval

The Food & Drug Administration (FDA) approved the drug in June, initially for wide use. But FDA’s approval letter conceded that the drug had limited clinical benefit for patients, even though it did appear to reduce a  protein on the brain called amyloid beta. High levels of that protein are associated with Alzheimer’s Disease but the evidence is weak that reducing amyloid beta improves brain function or reverses or slows the progression of Alzheimer’s.   

In July, FDA and Biogen agreed to change the label to clarify the drug only should be used for patients with early-stage Alzheimer’s disease, the population studied in Biogen’s clinical trials. The drug maker stopped those trials before they were complete after they showed mixed but limited positive benefits.

Given the questionable benefits of Aduhelm and the known side effects, CMS made the right call. Patients and their physicians deserve to know the results of a careful and complete trial.

You Might Also Like

Residing Paycheck to Paycheck: 9 Genius Methods To Cease It Ceaselessly – Dollarsanity

10 Tricks to Reside Frugally After Retirement – Dollarsanity

Tips on how to Price range Your Money Utilizing Dave Ramsey’s Budgeting Percentages – Dollarsanity

How To Make A Funds: 12 Simple Methods To Do It (The Full Information) – Dollarsanity

10 Outdated-Normal Cleansing Suggestions from Grandma – Dollarsanity

TAGGED:MoneyThe Forbes Journal
Share This Article
Facebook Twitter Email Copy Link Print
Derek McInnes: Hearts success my focus, not Rangers hypothesis | Premiership supervisor of month says future is ‘firmly’ at Jambos
Sports

Derek McInnes: Hearts success my focus, not Rangers hypothesis | Premiership supervisor of month says future is ‘firmly’ at Jambos

Derek McInnes has advised Sky Sports activities Information his job is "firmly at Hearts" as he continues to be linked with changing Russell Martin at Rangers.Many imagine the previous Ibrox…

By Tycoon Herald 5 Min Read
Questions stay about deceased Israeli hostages in Gaza
October 14, 2025
Gavin Newsom Compares Trump & Netanyahu to ‘Dumb and Dumber’ Characters
October 14, 2025
UK dangers increased inflation turning into entrenched, IMF warns
October 14, 2025
Leadership Coaching for the Actual World
October 14, 2025

You Might Also Like

Wedding ceremony On A Funds: Get K-Like Wedding ceremony For K or Much less – Dollarsanity
Money

Wedding ceremony On A Funds: Get $30K-Like Wedding ceremony For $5K or Much less – Dollarsanity

By Tycoon Herald 19 Min Read
80 Issues I Stopped Shopping for to Save Money Quick and Pay Off Debt – Dollarsanity
Money

80 Issues I Stopped Shopping for to Save Money Quick and Pay Off Debt – Dollarsanity

By Tycoon Herald 38 Min Read
50 Small Business Concepts For Ladies – Dollarsanity
Money

50 Small Business Concepts For Ladies – Dollarsanity

By Tycoon Herald 35 Min Read

More Popular from Tycoon Herald

MEET THE FATHER OF COADUNATE ECONOMIC MODEL
BusinessTrending

MEET THE FATHER OF COADUNATE ECONOMIC MODEL

By Tycoon Herald 2 Min Read
Woman Sentenced to 7 Days in Jail for Walking in Yellowstone’s Thermal Area

Woman Sentenced to 7 Days in Jail for Walking in Yellowstone’s Thermal Area

By Tycoon Herald
Empowering Fintech Innovation: Swiss Options Partners with Stripe to Transform Digital Payments
InnovationTrending

Empowering Fintech Innovation: Swiss Options Partners with Stripe to Transform Digital Payments

By Tycoon Herald 7 Min Read
Leadership

3 Powerful Characteristics Of A Genuinely Humble Leader

A humble leader is a people-first leader whereas a fake humble leader is a self-first leader.…

By Tycoon Herald
Business

5 Trends Retailers May Not See Coming Until It Is Too Late

Photo by: zz/KGC-254/STAR MAX/IPx 2021 3/6/21 General views of the Amazon Fresh Grocery Store on ...…

By Tycoon Herald
Trending

U.S. Blew Up a C.I.A. Post Used to Evacuate At-Risk Afghans

A controlled detonation by American forces that was heard throughout Kabul has destroyed Eagle Base, the…

By Tycoon Herald
Leadership

Northern Lights: 17 Best Places To See Them In 2021

Who doesn’t dream of seeing the northern lights? According to a new survey conducted by Hilton, 59% of Americans…

By Tycoon Herald
Real Estate

Exploring Bigfork, Montana: A Little Town On A Big Pond

Bigfork, Montana, offers picturesque paradise in the northern wilderness. National Parks Realty With the melting of…

By Tycoon Herald
Leadership

Leaders Need To Know Character Could Be Vital For Corporate Culture

Disney's unique culture encourages young employees to turn up for work with smiles on their faces.…

By Tycoon Herald
The Tycoon Herald

Tycoon Herald: Your instant connection to breaking stories and live updates. Stay informed with our real-time coverage across politics, tech, entertainment, and more. Your reliable source for 24/7 news.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact Us

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Terms of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© Tycoon Herald. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?